Proteins and Peptides

01 Jul 2021 Adocia Initiates BC LisPram Phase 1 Clinical Trial in Pump for People with Type 1 Diabetes
01 Jul 2021 Savara Announces First Patient Dosed in Pivotal Phase 3 Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Trial
01 Jul 2021 Jazz Pharmaceuticals Announces U.S. FDA Approval of Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
29 Jun 2021 BRIM Biotechnology’s lead candidate BRM421 for Dry Eye Syndrome shows promising results in Phase II clinical trials
29 Jun 2021 Investigational 2.0 mg dose of Ozempic® (semaglutide) demonstrates superior reductions in blood sugar vs Ozempic® 1.0 mg in adults with type 2 diabetes in a phase 3 trial
26 Jun 2021 Pieris Pharmaceuticals Announces Inhaled CTGF Inhibitor PRS-220 for Idiopathic Pulmonary Fibrosis and 17 Million Dollar Grant From Bavarian Government To Accelerate Program Development for Post-COVID-19 Pulmonary Fibrosis
25 Jun 2021 Aurinia Announces Licensing Partner Otsuka Filed Initial Marketing Authorization Application (MAA) for Voclosporin with the European Medicines Agency (EMA)
24 Jun 2021 Revolo Biotherapeutics Announces US FDA Approval of IND Application for Phase 2 Trial of ‘1104 in Eosinophilic Esophagitis
24 Jun 2021 Entera Bio Announces Excellent Topline Phase 2 BMD Data for EB613, the Study Met Its Primary and Key Secondary Endpoints
24 Jun 2021 Clovis Oncology Announces LuMIERE Clinical Trial Evaluating Novel Peptide-Targeted Radionuclide Therapy FAP-2286 Now Open for Enrollment
24 Jun 2021 Gemini Therapeutics Announces Initial Data From Its Ongoing Phase 2a Study of GEM103 in Patients With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
17 Jun 2021 Novartis Receives FDA Breakthrough Therapy Designation for Investigational 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
16 Jun 2021 RayzeBio Secures $108 Million Series C Financing to Drive Forward Its Pipeline of Targeted Radiopharmaceuticals for Cancer
16 Jun 2021 Hugel America, Inc. Announces U.S. FDA Acceptance of Biologics License Application (BLA) for LetibotulinumtoxinA for Injection to Treat Glabellar (Frown) Lines
15 Jun 2021 Innovent Announces First Overweight or Obese Subject Dosed in A Phase 2 Clinical Trial of IBI362 (a GLP-1 and Glucagon Receptor Dual Agonist) in China
13 Jun 2021 Alluzience®, the first ready-to-use BoNT-A neuromodulator, receives positive decision for use in Europe
05 Jun 2021 Wegovy™ (semaglutide 2.4 mg), the first and only once-weekly GLP-1 therapy for weight management, approved in the US
05 Jun 2021 Liminal BioSciences Announces FDA Approval for its Biologics License Application for Ryplazim® (plasminogen, human-tvmh)
04 Jun 2021 Alkermes Presents New Data on Nemvaleukin Alfa at 2021 American Society of Clinical Oncology Annual Meeting
04 Jun 2021 Tarveda Therapeutics Presents Promising Phase 2 Data of PEN-221 in Gastrointestinal Mid-gut Neuroendocrine Tumors
04 Jun 2021 U.S. FDA Accepts PharmaEssentia’s BLA Resubmission for ropeginterferon alfa-2b-njft for the Treatment of Polycythemia Vera (PV)
03 Jun 2021 Lupin announces U.S. FDA acceptance for Pegfilgrastim Biosimilar application
29 May 2021 Novo Nordisk resubmits once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes for US regulatory approval
27 May 2021 Horizon Therapeutics plc Initiates ADVANCE Trial Evaluating KRYSTEXXA® (pegloticase injection) with Methotrexate for People Who Previously Developed Anti-Drug Antibodies on KRYSTEXXA Monotherapy
27 May 2021 Novartis and Molecular Partners announce start of EMPATHY clinical trial for ensovibep for the treatment of COVID-19

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up